

NanoSphere Health Sciences Inc.

News Release

July 2, 2021 – Vancouver, BC. NanoSphere Health Sciences Inc. (CSE: NSHS) (“Nanosphere” or the “Company”) announces that, further to its news release of June 11, 2021, the record date for the consolidation of its common shares on the basis of 20 pre-consolidated common shares for 1 new post-consolidated common share (the “Consolidation”), will be July 8, 2021. Outstanding options, warrants and other convertible securities will likewise be adjusted for the Consolidation, with the number of underlying common shares and exercise prices being adjusted accordingly.

There will be no change to the Company’s name or trading symbol. No fractional common shares will be issued, and fractions of less than one-half of a share will be cancelled and fractions of at least one-half of a share will be converted to a whole common share. Following the Consolidation and subject to rounding, the Company expects to have approximately 5,471,753 common shares issued and outstanding, and approximately 426,516 common shares reserved for issuance.

Letters of Transmittal will be mailed shortly to registered shareholders who hold share certificates, with instructions for the exchange of existing share certificates for new share certificates. Shareholders holding uncertificated shares (such as BEO, NCI and DRS positions) will not receive a Letter of Transmittal but will have their holdings adjusted electronically by the Company’s transfer agent, and need not take any further action to exchange their pre-Consolidation shares for post-Consolidation shares.

The Company expects that the CSE will issue a bulletin in due course, confirming the date on which the Company’s common shares will commence trading on the CSE on a post-Consolidation basis.

On behalf of the Board of Directors

“*Michael Iverson*”

Michael Iverson, Chairman

For further information please contact:

Michael Iverson

Tel: 604-351-3351

Email: maiverson@telus.net

The Canadian Securities Exchange has neither reviewed or approved the contents of, nor accepts responsibility for the adequacy or accuracy of, this news release.

About NanoSphere

NanoSphere Health Sciences is a nanobiotechnology firm specializing in proprietary delivery systems for therapeutic agents. Our patented technology transforms our strategic partner’s *good products into great products*, further differentiating them in their respective markets.

For more information on NanoSphere, please visit: www.NanoSphereHealth.com.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans,